Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
•
Systemic lupus erythematosus
•
Cyclophosphamide
•
General Rheumatology
•
Infectious Disease
•
Tuberculosis
•
Latent Tuberculosis
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
Related Questions
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
How would you approach management of a patient with mixed cryoglobulinemic vasculitis with predominant skin involvement and no major organ involvement?
Do you find HZV titers useful in diagnosing shingles sine herpete?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
How would you approach management of nodular scleritis in the setting of suspected GCA?
For patients with SLE, is there an ANC level for which you would hold or adjust hydroxychloroquine in an asymptomatic patient?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?